JP Morgan Chase’s Xtant Medical Holdings XTNT Stock Holding History

JP Morgan Chase’s Portfolio XTNT Stock Details XTNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-107	Closed	-$69	–	7833
2025 Q3	$69	Sell	107 -1	-0.9%	-$1	﹤0.01%	7198
2025 Q2	$80	Buy	108 +6	+6%	+$3	﹤0.01%	6866
2025 Q1	$48	Sell	102 -9	-8%	-$5	﹤0.01%	6994
2024 Q4	$49	Hold	111	–	–	﹤0.01%	7139
2024 Q3	$75	Sell	111 -1	-0.9%	-$1	﹤0.01%	7043
2024 Q2	$71	Sell	112 -13,844	-99%	-$11K	﹤0.01%	6961
2024 Q1	$16.3K	Buy	13,956 +13,869	+15,941%	+$15.2K	﹤0.01%	6266
2023 Q4	$98	Buy	87 +55	+172%	+$65	﹤0.01%	7125
2023 Q3	$35	Buy	+32	New	+$34	﹤0.01%	7062
2019 Q1	–	Sell	-89	Closed	–	–	6089
2018 Q4	$0	Buy	+89	New	+$287	﹤0.01%	5970

Other funds holding XTNT

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase's XTNT Position: Q4 2025 in Review

JP Morgan Chase sold out of Xtant Medical Holdings (XTNT) in Q4 2025, closing a stake of 107 shares — an estimated $69 sold.

JP Morgan Chase first reported a position in XTNT in Q4 2018 and held it in 10 quarters. The position peaked at $16.3K in Q1 2024. 35 funds tracked by Wall St. Rank hold XTNT as of Q4 2025.

JP Morgan Chase reported no remaining Xtant Medical Holdings position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 107 Xtant Medical Holdings shares in Q4 2025, an estimated $69.
JP Morgan Chase first reported a position in Xtant Medical Holdings in Q4 2018 and held it in 10 quarters.
JP Morgan Chase's Xtant Medical Holdings position peaked at $16.3K in Q1 2024.
35 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.